Clinical Report: Long-term Real-World Outcomes of Anti-CGRP Monoclonal Antibodies

Overview

This study evaluated the long-term efficacy and adherence to anti-CGRP monoclonal antibodies for migraine prevention over three years. Results showed significant reductions in monthly migraine days and high treatment persistence, with most discontinuations occurring after treatment goals were met.

Background

Migraine is a prevalent condition that significantly impacts quality of life and daily functioning. While acute treatments exist, many patients require effective prophylactic options. Anti-CGRP monoclonal antibodies represent a novel approach in migraine management, yet long-term real-world data on their effectiveness and adherence is limited, making this study essential for clinical practice.

Data Highlights

Key Findings

• 56% of subjects maintained treatment for 3 years.
• Monthly migraine days reduced from 12.0 to 5.6 over 36 months.
• Significant improvements in MIDAS, HIT-6, and VAS scores (p < 0.01).
• Responder rates at 36 months were 55.6% for ≥50% reduction in MMDs.
• 24% of discontinuations were due to achieving treatment objectives.

Clinical Implications

The findings support the use of anti-CGRP monoclonal antibodies as a long-term preventive treatment for migraine, with a favorable safety profile and high adherence rates. Clinicians should consider these therapies for patients who have not responded adequately to acute treatments.

Conclusion

Anti-CGRP monoclonal antibodies demonstrate sustained efficacy and tolerability in real-world settings, reinforcing their role in personalized migraine management strategies.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. AHS Consensus Statement CGRP-Targeting Therapies for Prevention of Migraine Guideline Summary 2024 - Guideline Central
6. Review: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic Migraine | Current Pain and Headache Reports | Springer Nature Link
7. Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review | The Journal of Headache and Pain | Springer Nature Link
8. AHS Consensus Statement CGRP-Targeting Therapies for Prevention of Migraine Guideline Summary 2024 - Guideline Central
9. Review: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic Migraine | Current Pain and Headache Reports | Springer Nature Link
10. Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review | The Journal of Headache and Pain | Springer Nature Link